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Background: Research towards the application of nanoparticles as carrier vehicles for the 
delivery of therapeutic agents is increasingly gaining importance. The angiogenic growth   factors, 
human vascular endothelial growth factor (VEGF) and human angiopoietin-1 are known to 
prevent vascular endothelial cell apoptosis and in fact to stimulate human vascular endothelial 
cell (HUVEC) proliferation. This paper aims to study the combined effect of these bioactive 
proteins coencapsulated in human serum albumin nanoparticles on HUVECs and to evaluate 
the potential application of this delivery system towards therapeutic angiogenesis.
Methods and results: The angiogenic proteins, human VEGF and human angiopoietin-1, 
were coencapsulated in albumin nanoparticles for better controlled delivery of the proteins. 
The application of a nanoparticle system enabled efficient and extended-release kinetics of the 
proteins. The size of the nanoparticles crosslinked with glutaraldehyde was 101.0 ± 0.9 nm and 
the zeta potential was found to be -18 ± 2.9 mV . An optimal concentration of glutaraldehyde 
for the nanoparticle coating process was determined, and this provided stable and less toxic 
nanoparticles as protein carriers. The results of the study indicate that nanoparticles crosslinked 
with glutaraldehyde produced nanoparticles with tolerable toxicity which provided efficient and 
controlled release of the coencapsulated proteins. The nanoparticles were incubated for two 
weeks to determine the release profiles of the proteins. At the end of the two-week incubation 
period, it was observed that 49% ± 1.3% of human angiopoietin-1 and 59% ± 2.1% of human 
VEGF had been released from the nanoparticles. The proliferation and percent apoptosis of the 
HUVECs in response to released proteins was observed.
Conclusion: The results indicate that the released proteins were biologically active and the 
combined application of both the proteins demonstrated a significant highly proliferative and 
antiapoptotic effect on HUVECs as compared with the effect demonstrated by the individual 
proteins released. These studies could serve as a basis to encourage further research into the 
potential in vivo application of these protein-loaded nanoparticles in the field of therapeutic 
angiogenesis.
Keywords: growth factors, encapsulation, nanoparticles, nanobiotechnology, angiogenesis, 
regenerative medicine
Introduction
Vasculogenesis and angiogenesis are the two essential mechanisms that implement 
the development of the vascular network.1,2 Vasculogenesis is a process in the early 
development of an individual during blood vessel network formation, whereas angio-
genesis which is a similar process, does not occur only at the time of the   creation but 
is a mechanism that occurs throughout the organism’s life. Angiogenesis is basically 
associated with the proliferation, migration, and remodeling of fully   differentiated International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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endothelial cells and involves sprouting of new smaller blood 
vessels from pre-existing ones and repair of damaged blood 
vessels at the site of an injury. It is known that programmed 
cell death, ie, apoptosis, is required for normal development 
of multicellular organisms, whereby unwanted cells are elimi-
nated during physiological and certain pathological condi-
tions.3 However, it has also been shown that the dysregulation 
of endothelial cell apoptosis has a major regulatory effect 
on the establishment of the primordial vascular network, 
termed vasculogenesis in the embryo, causing severe hemor-
rhage and finally leading to embryonal death. Counteracting 
proliferation, endothelial cell apoptosis in excess may limit 
angiogenesis, thus leading to vessel regression. It is hence 
evident that inhibition of endothelial cell apoptosis can serve 
as a potential therapeutic target, especially in patients suffer-
ing from ischemic diseases for which prevention of apoptosis 
could improve angiogenesis and vasculogenesis.
Several growth factors and proteins have demonstrated an 
ability to prevent vascular endothelial cell apoptosis and in 
fact stimulate endothelial cell proliferation. Vascular endothe-
lial growth factor (VEGF) is a mitogenic and chemotactic 
factor for endothelial cells, and seems to play a vital role in the 
protection of these cells against apoptosis.4–6 The use of human 
VEGF as a potential stimulant in therapeutic angiogenesis 
has been widely demonstrated.7–14 However, there is still an 
uncertainty as to whether the presence of human VEGF alone 
would suffice in the achievement of functional and mature 
vessels lined with vascular smooth muscles or pericytes. 
There is evidence that excessive human VEGF expression 
could bring about pathological and immature vessel formation 
and enhanced vascular wall permeability, and could lead to 
angioma formation.15–17 In this context, research has shown 
that the ligand of TIE-2 receptor, angiopoietin-1, has the abil-
ity to stabilize and assist in the maturation of blood vessels,18–20 
and in fact abrogates endothelial cell apoptosis.21,22 However, 
there has been debate over the role of human   angiopoietin-1 
as an endothelial cell mitogen. While some studies have 
demonstrated human angiopoietin-1 to be a potent mitogen 
of endothelial cells,23 others have pointed out that human 
angiopoietin-1 either failed to induce proliferation,24 or 
did not cause a significant increase in the proliferation.25 
  However, on the whole, the administration of a combination 
of human angiopoietin-1 with human VEGF may prove to be 
an efficient strategy for therapeutic angiogenesis. Moreover, 
several studies have also demonstrated that the application 
of multiple growth factors for therapeutic applications has a 
greater impact than single growth factor delivery.26–28
Extensive research is being carried out to discover the 
potential of using recombinant proteins towards therapeutic 
applications. However, due to their very limited in vivo half-
lives, the proteins have to be administered through multiple 
injections to achieve the desired therapeutic effect. These 
macromolecules also have high molecular weights which lead 
to low bioavailability and high aqueous solubility, and they 
are incapable of diffusing through biological membranes.29,30 
It is thus evident that appropriate delivery vehicles need to 
be developed for these macromolecules, which are in fact 
very unstable, so as to protect them from degradation in 
the biological environment of the organism. The potential 
to use these molecules for therapeutic applications greatly 
depends on the use of a suitable vehicle for delivery. Thus, 
numerous strategies have been applied towards the design 
of appropriate vehicles for efficient sustained growth factor 
delivery.31 However, the use of nanoparticles as protein deliv-
ery systems has gained interest. The use of nanoparticles 
has several advantages over microparticle encapsulation.32 
By encapsulating the macromolecules, the physicochemical 
properties of the particles allow more controlled and continu-
ous protein release over a period of several weeks.
Amongst the existing delivery systems, nanoparticles 
based on natural biopolymers have been shown to be very 
promising as compared with those made of synthetic mate-
rials. Albumin is a physiological protein that is found in 
abundance in the blood and can be purified easily. In our 
study, we made use of human serum albumin as the develop-
ing material for the delivery system. Human serum albumin 
has a molecular weight of 66 kDa and has the ability to 
bind to hormones, long-chain fatty acids, metal ions with 
high affinity, and vitamins, thus serving as a transport and 
depot protein for a variety of compounds.33 Studies have 
also shown that human serum albumin binding results in 
decreased toxicity and an increase in the in vivo half-life 
of the bound ligands.34 In the literature, three methods 
exist for the preparation of human serum albumin-based 
nanoparticles based on emulsion formation, desolvation, 
or coacervation processes.35–37 In order to stabilize the 
resulting nanoparticles, glutaraldehyde can be used as the 
crosslinking agent.37,38 However, to date, the application of 
nanoparticles towards the encapsulation of growth factors 
is lacking. The objective of this study was to investigate the 
feasibility of entrapping the growth factors, human VEGF 
and human angiopoietin-1, in nanoparticles crosslinked with 
glutaraldehyde to enable potential application in therapeutic 
angiogenesis.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Materials and methods
Materials
Human serum albumin (fraction V , purity 96%–99%), bovine 
serum albumin, guanidine hydrochloride, and 8% glutaral-
dehyde were purchased from Sigma Aldrich (Oakville, ON, 
Canada). Human VEGF, human angiopoietin-1, and their 
respective enzyme-linked immunosorbent assay (ELISA) kits 
were purchased from R & D systems (Minneapolis, MN), 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation 
MTS Assay kit (Promega, Madison, WI) was used to detect 
cytotoxicity and cell proliferation. Antibodies against human 
VEGF and human angiopoietin-1 were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA).
cell culture
Human vascular endothelial cells (HUVECs; Sciencell, 
Carlsbad, CA) were cultured and expanded on tissue 
  culture plates according to the manufacturer’s instructions. 
They were cultured in endothelial cell medium (Sciencell) 
  supplemented with 5% (v/v) fetal bovine albumin and placed 
in an incubator containing 5% CO2 at 37°C. The cells used 
in this study were from between passages 2 and 5.
Preparation of nanoparticles
As demonstrated by our group earlier, human serum   albumin 
nanoparticles were prepared using the pH-coacervation tech-
nique.39 Briefly, 100 mg of human serum albumin protein was 
added to 2 mL of 10 mM NaCl solution in a glass vessel under 
constant stirring at room temperature. The pH was brought to 
8 by the addition of 0.1 N NaOH. Then, 14 µL of 0.5 mg/mL 
of human angiopoietin-1, 1 µL of 0.5 mg/mL human VEGF, 
and 1 µL of 0.5 mg/mL of bovine serum albumin dissolved 
in endothelial cell medium (with or without 5% fetal bovine 
albumin) was added into the above solution, and this aque-
ous phase was then desolvated with dropwise addition of 
ethanol 4 mL at a constant rate of 1 mL/min to form the 
nanoparticles. The concentration of protein added during 
the nanoparticle preparation was optimized based on the 
fact that when the inhibitory doses of human   angiopoietin-1 
was almost 10 times more than those for human VEGF, both 
caused identical antiapoptotic effects in HUVECs and, using 
a combination of human angiopoietin-1 with human VEGF, 
produced a significantly greater antiapoptotic effect.22 Nano-
particles containing bovine serum albumin were taken as the 
negative control. The protein-encapsulated nanoparticles 
formed were then stabilized by coating with 40 µL of 5% 
glutaraldehyde. The coated nanoparticles were purified by 
  ultracentrifugation at 20,000 g for 15 minutes, and the pellet 
was redispersed into double-distilled H2O to original volume. 
The purification process was carried out three times, with 
each redispersion step performed in a Bransonic® Ultrasonic 
Cleaner 2510 bath (Branson, Danbury, CT) for 15 minutes. 
The entire procedure of particle preparation was carried out 
under sterile conditions, and all the solutions used during 
preparation were sterilized by passing them through 0.20 µm 
sterile filters before use. The encapsulation efficiency of 
both the proteins was determined in terms of the amount of 
human angiopoietin-1 and human VEGF transformed into 
nanoparticles before coating using human angiopoietin-1 
and human VEGF ELISA kits. The nanoparticles were cen-
trifuged at 20,000 g for 15 minutes at room temperature to 
separate the nanoparticles from the supernatant. Percentage 
encapsulation efficiency was calculated as:
 initial amount of growth factor growth factor amount in t - h he supernatant
initial amount of growth factor
100

 

  ×
Particle size and zeta potential  
of nanoparticles
The particle size, zeta potential, and polydispersity index 
of the nanoparticles was measured by the technique of 
electrophoretic laser Doppler anemometry using a Zeta 
Potential Analyzer (Brookhaven Instruments Corporation, 
Holtsville, NY). For zeta potential determination, 0.005 M 
phosphate buffer with pH 7.0 was used. The ZetaPlus   Particle 
Sizer software (version 4.11; Brookhaven Instruments 
  Corporation) was used to determine the size distribution of 
the nanoparticles and the Zeta Potential Analyzer Version 
3.57 (Brookhaven Instruments Corporation) was the software 
used for the zeta potential. Both the particle size and the zeta 
potential were measured for three batches of nanoparticles, 
and each measurement was obtained after taking the average 
of the three runs.
Nanoparticle surface characterization
Scanning electron microscopy (SEM) was used to study 
the morphological characteristics of the nanoparticles. The 
nanoparticles were dispersed in double-distilled H2O and 
then dried with natural convection under room temperature. 
The samples were then examined under S4700 FEG-SEM 
(Hitachi, Oakville, Canada).
Transmission electron microscopy (TEM) was used to 
obtain the size characterization. The nanoparticles were 
suspended in 1 × phosphate-buffered saline and analyzed on 
CM200 FEG-TEM (Philips, Markham, Canada).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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For the atomic force microscopy (AFM) measurements, 
the nanoparticle samples were sonicated for 5 minutes, and 
1 µL of the sample was dropped on to the surface of the 
discs and dried using the conventional method. Images were 
produced with Nanoscope III AFM (Digital Instruments, 
Palo Alto, CA) using silicon cantilever in tapping mode and 
analyzed using Nanoscope software (version 5.12r5; Digital 
Instruments).
In vitro cytotoxicity of nanoparticles  
with MTs assay
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation 
MTS Assay kit (Promega) was used to assess the in vitro 
cytotoxicity of the various concentrations of   glutaraldehyde 
on HUVECs.39 The HUVECs were seeded at a density 
of 2 × 104 cells/well in a 96-well plate in fresh medium. 
  Twenty-four hours after seeding, the HUVECs were 
washed with phosphate-buffered saline and incubated 
with nanoparticles crosslinked with 40 µL of 1.5%, 3%, 
4.5%, 6%, and 7.5% and control nanoparticles without 
glutaraldehyde crosslinking for 96 hours. The relative 
HUVEC viability was determined by MTS assay, which 
was performed as per the manufacturer’s protocol. Briefly, 
after 96 hours of incubation, the HUVECs were washed 
with phosphate-buffered saline and fresh endothelial 
cell medium was added to the wells. This was followed 
by the addition of 20 µL of MTS solution to each well 
and the cells were incubated for four hours at 37°C. The 
measurement of the absorbance was carried out using the 
1420–040 Victor3TM Multilabel Counter (Perkin Elmer, 
Woodbridge, Canada) at 490 nm. An optimal   concentration 
of glutaraldehyde was chosen to form the coating of the 
protein-loaded nanoparticles.
In vitro release of coencapsulated  
human angiopoietin-1 and human VegF
The protein-loaded nanoparticles were coated with 40 µL 
of 5% glutaraldehyde for this study. The nanoparticles were 
incubated with 5 mL of endothelial cell medium with 1% 
penicillin/streptomycin at 37°C under constant shaking. 
The experiment was carried out in triplicate. The samples 
were then centrifuged at 20,000 g for 15 minutes at the indi-
cated time points and 0.4 mL of supernatant was removed. 
In order to maintain a constant volume, the same amount 
of fresh endothelial cell medium was added back to the 
pellet. The amount of human angiopoietin-1 and human 
VEGF protein released into the supernatant was determined 
using human angiopoietin-1 and human VEGF ELISA kits, 
  respectively, according to the manufacturers’ protocols.
hUVec proliferation assay
The bioactivity of released human VEGF and human 
  angiopoietin-1 dissolved in endothelial cell medium 
(supplemented with 5% fetal bovine albumin) from the 
nanoparticles was evaluated in vitro by determining the 
proliferative capacity of the HUVECs. The CellTiter 
96 Aqueous   Non-Radioactive Cell Proliferation MTS 
Assay kit (Promega) was used to assess proliferation of the 
human vascular endothelial cells treated with nanoparticle 
supernatant.40,41 The HUVECs were plated in a density 
of 2 × 104 cells/well in a 96-well plate in endothelial cell 
medium containing 5% (v/v) fetal bovine albumin. After 
24 hours, the endothelial cell medium was removed and 
the cells were then incubated for 96 hours with 0.1 µL of 
  nanoparticle supernatant, nanoparticle supernatant with 
excess human VEGF antibody, and nanoparticle supernatant 
with excess human angiopoietin-1 antibody released from the 
  nanoparticles into the endothelial cell medium on days 2, 8, 
and 14. The results from the ELISA were used to determine 
the concentration of human angiopoietin-1 and human VEGF 
in the nanoparticle supernatant. Control samples received the 
same amount of endothelial cell medium (supplemented with 
5% fetal bovine albumin) and nanoparticle supernatant with 
bovine serum albumin. The relative HUVEC viability was 
determined by MTS assay which was performed as per the 
manufacturer’s protocol. Briefly, after 96 hours of incubation, 
the HUVECs were washed with phosphate-buffered saline, 
and fresh endothelial cell medium was added to the wells. 
This was followed by the addition of 20 µL of MTS solution 
to each well, and the cells were incubated for four hours at 
37°C The measurement of the absorbance was carried out 
using the 1420–040 Victor3TM Multilabel Counter (Perkin 
Elmer) at 490 nm.
hUVec apoptosis assay
To determine the percentage apoptosis, nanoparticles were 
prepared using the same particle preparation protocol 
as before, but the proteins were dissolved in serum-free 
endothelial cell medium (without 5% fetal bovine albumin) 
instead of endothelial cell medium with 5% fetal bovine 
albumin, and then added to the human serum albumin 
solution. The nanoparticles obtained were then incubated 
with 5 mL of serum-free endothelial cell medium with 1% 
penicillin-streptomycin at 37°C, with constant shaking. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The samples were then centrifuged at the indicated time 
points, and 0.4 mL of supernatant was removed. In order 
to maintain a constant volume, the same amount of fresh 
serum-free endothelial cell medium was added back to 
the pellet. The HUVECs were then seeded onto a 96-well 
plate at a cell density of 2 × 104 cells per well in endothelial 
cell medium supplemented with 5% fetal bovine serum 
and incubated at 37°C for 24 hours. After the incubation 
period, the cells were washed three times with phosphate-
buffered saline, and the medium was replaced with 0.1 mL 
of nanoparticle supernatant, nanoparticle supernatant with 
excess human VEGF antibody, or nanoparticle supernatant 
with excess human angiopoietin-1 antibody from days 2, 
8 and 14, and incubated for 96 hours. Control cultures 
received the same amount of serum-free endothelial cell 
medium without the addition of human VEGF and human 
angiopoietin-1 proteins and nanoparticle supernatant con-
taining bovine serum albumin. The numbers of cells floating 
in each well were collected after phosphate-buffered saline 
washing and counted. The number of apoptotic cells in the 
adherent cells was then determined after 96 hours using 
a MitoTracker® Red CMXRos kit and DAPI nucleic acid 
staining (In  vitrogen, Burlington, Canada), according to the 
manufacturer’s instructions, and were counted from random 
locations in the well using fluorescence microscopy.42 Both 
the staining techniques gave similar results and apoptosis 
was demonstrated as the percentage of apoptotic adherent 
cells and floating cells in a well. The experiment was   carried 
out in triplicate.
Results and discussion
characterization of nanoparticles
In this study, the nanoparticles were prepared by a pH- 
coacervation technique followed by glutaraldehyde 
  crosslinking. Coacervation agents, such as ethanol, are 
widely used in protein purification processes, and nano-
particles are prepared by addition of coacervation agents to 
the protein solution.43 The nanoparticles were prepared by 
adjusting the pH of the human serum albumin solution to 
8.0 and controlling the amount of coacervation agent to form 
nanoparticles of size 101.0 ± 0.9 nm, as shown in Figure 2A. 
It is known that the size of the resultant   nanoparticles 
depends on the amount of the coacervation agent, but not 
on the amount of glutaraldehyde added or on the crosslink-
ing procedure.37
The TEM, SEM, and AFM micrographs of the nanopar-
ticles illustrated that the particles were properly dispersed, 
spherically-shaped, and had smooth surface characteristics, 
as shown in Figure 1. Figure 1A is a TEM image of the 
nanoparticles before ultrasonication, which indicates that, 
before ultrasonication, the nanoparticles form clusters and 
are not properly dispersed. Figure 1B is the TEM image 
of the nanoparticles after ultrasonication for 15 minutes. 
Here it is demonstrated how ultrasonication assists in 
separating out the particles more uniformly and the par-
ticles are properly dispersed. Figure 1C gives the TEM 
image of the nanoparticles after magnification. Figure 1D 
is the SEM image for the nanoparticles crosslinked with 
40 µL of 5% (w/v) glutaraldehyde which demonstrates 
the smooth surface characteristics of the nanoparticles. 
Figure 1E provides the three-dimensional AFM image of 
the nanoparticles.
The surface charge and size of the particles are the two 
main surface characteristics that influence the biodistribution 
of the nanoparticles upon administration. The zeta potential 
of the glutaraldehyde-crosslinked nanoparticles decreases 
when the concentration of glutaraldehyde is increased.37 
Zeta potential measurements were performed in phosphate 
buffer at pH 7.0 because the pH and ionic strength of the 
dilution medium affects the magnitude of the zeta potential. 
The value was found to be in accordance with the results 
shown by Lin et al.43 The protein nanoparticles were nega-
tively charged and the zeta potential was -18 ± 2.9 mV at 
pH 7.0 as shown in Figure 2B. The polydispersity index 
was found to be 0.3.
Determination of cytotoxic effects  
of nanoparticles on hUVecs
Glutaraldehyde has been widely used as a crosslinking agent 
in the preparation of nanoparticles. However, it is known to 
induce cytotoxicity, and higher concentrations of glutaralde-
hyde in particle preparation can lead to an increased toxicity 
to the cells. Therefore, an optimal amount of glutaraldehyde 
to be used in the particle preparation was determined for 
stable and less toxic nanoparticles. The cytotoxicity of the 
blank nanoparticles crosslinked with a series of glutaralde-
hyde concentrations was studied by incubating HUVECs 
for 96 hours with the nanoparticles. MTS assay was used to 
determine the percentage of viable cells compared with the 
initial number of cells. As shown in Figure 3, human serum 
albumin nanoparticles without glutaraldehyde coating showed 
a cell viability of above 90% after 96 hours. Increasing the 
concentration of glutaraldehyde in the particle preparation 
increased the cytotoxicity of the nanoparticles to the seeded International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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HUVECs; 40 µL of 5% (w/v) glutaraldehyde was chosen as 
the optimal concentration for the nanoparticle preparation 
which resulted in the formation of stable and uniform par-
ticles suitable for protein delivery. It should be noted that, 
in the future, further research might be necessary to replace 
the application of glutaraldehyde with more biocompatible 
polymers, but for this study, nanoparticles crosslinked with 
glutaraldehyde loaded with human angiopoietin-1 and human 
VEGF were studied further to investigate if the bioactivity 
of the proteins was maintained.
AB
D C
E
Figure 1 The TeM, seM, and AFM micrographs of the nanoparticles illustrate that the particles are properly dispersed, spherically-shaped, and have smooth surface 
characteristics. A, B, and C TeM images for the nanoparticles crosslinked with 40 µL of 5% (w/v) glutaraldehyde, 200 kV resolution. A) TeM image of the nanoparticles 
before ultrasonication which indicates that before ultrasonication the nanoparticles form clusters and are not properly dispersed. Bar, 500 nm. B) TeM image of the 
nanoparticles after ultrasonication for 15 minutes. here it is demonstrated how ultrasonication assists in separating out the particles more uniformly and the particles 
are properly dispersed. Bar, 100 nm. C) TEM image of the nanoparticles after magnification. Bar, 100 nm. D) seM image for the nanoparticles crosslinked with 40 µL of 
5% (w/v) glutaraldehyde which demonstrates the smooth surface characteristics of the nanoparticles, 2 kV resolution. Bar, 1 µm. E) Three-dimensional AFM image of the 
nanoparticles. Bar, 300 nm.
Abbreviations: TeM, transmission electron microscopy; seM, scanning electron microscopy; AFM, atomic force microscopy.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Encapsulation efficiency and release 
kinetics profile of proteins coencapsulated 
in nanoparticles
It has been shown that coating the nanoparticles with a 
crosslinking agent increases the encapsulation efficiency, 
reduces the initial burst release, and extends the protein release 
period to a slower more efficient release.44 In our studies, 
40 µL of 5% glutaraldehyde was taken as the optimal amount 
because the crosslinking agent producing stable nanoparticles 
with a reduced initial burst release and slower and steady 
extended-release profiles for both human angiopoietin-1 
and human VEGF. The encapsulation efficiency of human 
angiopoietin-1 and human VEGF during nanoparticle fabri-
cation was 49% and 55%, respectively. Cumulative release 
kinetics studies were conducted over two weeks to determine 
the release of human angiopoietin-1 and human VEGF from 
the nanoparticles in the culture medium. The release kinet-
ics profiles of both the proteins from the nanoparticles are 
illustrated in Figure 4. A burst release of both the proteins 
was observed within the initial two days followed by a lower 
steady release phase. The burst release amounts for human 
angiopoietin-1 and human VEGF were approximately 
617 ± 100 ng and 88 ± 10 ng, respectively, with lower steady 
release amounts of approximately 171.5 ng and 13.75 ng for 
Figure 2 Zeta potential and particle sizer. A) The nanoparticles were prepared by adjusting the ph of the human serum albumin solution to 8.0 and controlling the amount of 
coacervation agent to form nanoparticles of size approximately 101.0 ± 0.9 nm. B) The protein nanoparticles were negatively charged and the zeta potential was -18 ± 2.9 mV 
at ph 7.0. The zeta potential of the glutaraldehyde crosslinked nanoparticles decreases when the concentration of glutaraldehyde is increased. Zeta potential measurements 
were performed in phosphate buffer at ph 7.0 because ph and ionic strength of the dilution medium affects the magnitude of the zeta potential. The polydispersity index 
was found to be 0.3.
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human angiopoietin-1 and human VEGF, respectively. At 
the end of the 2-week incubation period, it was observed that 
49% of human angiopoietin-1 and 59% of human VEGF had 
been released from the nanoparticles. The cumulative release 
amounts for human angiopoietin-1 and human VEGF on day 
14 were 1680.7 ± 150 ng and 162.25 ± 17 ng, respectively.
retention of bioactivity of released  
human angiopoietin-1 and human  
VegF on hUVecs
Human VEGF is an endothelial cell-specific mitogen, 
which enhances vascular permeability, induces endothelial 
cell proliferation, and stimulates angiogenesis in vivo.7–14 
However, as discussed earlier, there has been debate over 
the role of human angiopoietin-1 as an endothelial cell 
mitogen. While some studies have demonstrated human 
angiopoietin-1 to be a potent mitogen of endothelial cells,23 
others have pointed out that human angiopoietin-1 either 
failed to induce   proliferation24 or did not cause a significant 
increase in proliferation.24 Our results indicate that the 
human VEGF in combination with human angiopoietin-1 
released from the nanoparticles in fact augments HUVEC 
proliferation significantly, which could enable the poten-
tial application of this delivery system for therapeutic 
angiogenesis.
The bioactivity of the human VEGF, human   angiopoietin-1, 
and bovine serum albumin in media released from the nano-
particles was evaluated in vitro by observing the proliferative 
capacity of the HUVECs. The CellTiter 96 AQueous 
Non-Radioactive Cell Proliferation MTS Assay kit was 
used to assess the proliferation of the HUVECs treated 
with nanoparticle supernatant. The results were illustrated 
as the percent increase in cell proliferation relative to the 
unstimulated control. As shown in Figure 5, the least cell 
proliferation occurs with nanoparticle supernatant containing 
human angiopoietin-1 (VEGF antibody added), moderate 
proliferation with nanoparticle supernatant containing 
human VEGF (angiopoietin-1 antibody added) and, finally, 
the highest proliferation is observed in the case of the 
nanoparticle supernatant containing both human VEGF and 
human   angiopoietin-1. As expected, the control nanoparticle 
supernatant containing bovine serum albumin produced 
negligible results. The effect of supernatant containing 
angiopoietin-1 on cell proliferation is relatively low compared 
with human VEGF, even though 10 times the amount of 
human VEGF was used for human angiopoietin-1. In each 
case, the cell proliferation increases over the two-week 
incubation period. This is due to the fact that there is more 
protein amount present in the nanoparticle supernatant 
as the days increase. The highest cell proliferation was 
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Figure 3 The cytotoxicity of the blank nanoparticles crosslinked with a series of glutaraldehyde concentrations was studied by incubating hUVecs for 96 hours with the 
nanoparticles. Percent cell viability over initial number of hUVecs treated with nanoparticles for up to 96 hours is shown. MTs assay was used to determine the cell viability 
after exposure to the nanoparticles. Nanoparticles without glutaraldehyde coating showed a cell viability of above 90% after 96 hours. Increasing the amount of glutaraldehyde 
in the particle preparation increased the cytotoxicity of the nanoparticles to the seeded hUVecs.
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observed for nanoparticle supernatant containing both human 
angiopoietin-1 and human VEGF, which was 89.62%, using 
nanoparticle supernatant containing human VEGF (angio-
poietin-1 antibody added) the proliferation was 67.79%, and 
using nanoparticle supernatant containing human angiopoi-
etin-1 (VEGF   antibody added) the proliferation was 5.87%. 
This shows that using both human angiopoietin-1 and human 
VEGF together will produce the best results.
retention of antiapoptotic activity  
of released human angiopoietin-1  
and human VegF on hUVecs
The serum deprivation method was used to induce apoptosis 
in HUVECs to demonstrate the antiapoptotic effect of both 
human angiopoietin-1 and human VEGF released from 
the nanoparticles. Under serum deprivation, the HUVECs 
seeded in the 96-well plate underwent apoptosis and became 
detached from the wells. As demonstrated by Kwak et al, 
human angiopoietin-1 acts as an apoptotic survival factor 
for endothelial cells.22 It was also shown that even when 
the inhibitory doses of human angiopoietin-1 was 10 times 
more than human VEGF, both caused identical antiapoptotic 
effects in HUVECs. In addition, it was also observed that 
during serum starvation of HUVECs, the antiapoptotic effect 
of human angiopoietin-1 was significantly increased when 
human VEGF was added, leading to a combined apoptotic 
inhibitory effect.
In our study, human angiopoietin-1 and human VEGF 
were loaded into nanoparticles and the combined antiapop-
totic effect of the proteins on the seeded HUVECs was 
demonstrated. It has been highlighted already that, due to 
their very limited in vivo half-lives, the proteins have to be 
administered through multiple injections so as to achieve the 
desired therapeutic effect. Moreover, these macromolecules 
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have high molecular weights, which leads to low bioavail-
ability, high aqueous solubility, and an inability to diffuse 
through biological membranes.29,30 The use of nanoparticles 
for the delivery of these   macromolecules, which are in fact 
very unstable, could aid in protecting them from degradation 
in the biological environment of the organism. The HUVECs 
were then seeded and 0.1 mL of nanoparticle supernatant 
from days 2, 8, and 14.   Nanoparticle supernatant containing 
bovine serum albumin and serum-free media without addition 
of human VEGF and human angiopoietin-1 taken as controls 
were added to the well and incubated for 96 hours. As shown 
in Figure 6, the HUVECs with serum-free control media and 
nanoparticle supernatant containing bovine serum albumin 
always showed a percent apoptosis above 90%. The release 
kinetics show that there is an increase in the cumulative 
amount of proteins released from the nanoparticles. In the 
study, 0.4 mL solution was taken from the nanoparticle 
supernatant and then replaced with serum-free media on the 
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Figure 5 Bioactivity of human angiopoietin-1 and human VegF loaded in nanoparticles. The proliferation of hUVecs in response to the nanoparticle supernatant was 
observed. hUVecs were seeded in a 96-well plate and the endothelial cell medium was replaced with nanoparticle supernatant with human VegF antibody, nanoparticle 
supernatant with human angiopoietin-1 antibody, nanoparticle supernatant containing both human angiopoietin-1 and human VegF, nanoparticle supernatant containing 
bovine serum albumin and endothelial cell medium (with 5% fetal bovine albumin) as the controls for 96 hours. The results were illustrated as the percent increase in cell 
proliferation relative to the unstimulated control. Least cell proliferation is observed with human angiopoietin-1 and maximum proliferation is observed in supernatant 
with a combination of both human angiopoietin-1 and human VegF. The supernatant with bovine serum albumin showed a negligible effect as expected. An increasing cell 
proliferation is observed over the two-week incubation period.
Abbreviations: VegF, vascular endothelial growth factor; hUVecs, human vascular endothelial cells.
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Figure 6 human angiopoietin-1 and human VegF were loaded into nanoparticles and the combined antiapoptotic effect of the proteins on the seeded hUVecs was 
demonstrated. hUVecs treated with serum-free control media without addition of human VegF and human angiopoietin-1 proteins, always showed a percent apoptosis 
above 90%. The release kinetics shows that there is an increase in the cumulative amount of proteins released from the nanoparticles. The percent apoptosis due to 
nanoparticle supernatant containing human angiopoietin-1 (human VegF antibody added) reduced from 31.5% to 27.06% for day 2 to day 14. similarly, percent apoptosis due 
to nanoparticle supernatant containing human VegF (human angiopoietin-1 antibody added) reduced from 29.6% to 27.74% for day 2 to day 14. The combined antiapoptotic 
effect of the nanoparticle supernatant containing human angiopoietin-1 and human VegF decreased from 16.44% to 10.42% at day 2 to day 14. Thus, in comparison with the 
control, cell apoptosis decreased dramatically (almost by 50%) with the application of supernatant from nanoparticles loaded with both the proteins.
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indicated days. The amount taken also has increasing protein 
content as the days increase. Due to this increasing protein 
presence, the percent cell apoptosis decreases from day 2 to 
day 14. The percent apoptosis due to nanoparticle supernatant 
containing human angiopoietin-1 (human VEGF antibody 
added) reduced from 31.5% to 27.06% for day 2 to day 14. 
Similarly, percent apoptosis due to nanoparticle supernatant 
containing human VEGF (human angiopoietin-1 antibody 
added) reduced from 29.6% to 27.74% from day 2 to 14. The 
combined antiapoptotic effect of the nanoparticle supernatant 
containing human angiopoietin-1 and human VEGF decreased 
from 16.44% to 10.42% for day 2 to day 14. Thus, in compari-
son with the control, the cell apoptosis decreased dramatically 
(almost by 50%) with the application of supernatant from 
nanoparticles loaded with both the proteins.
Figure 7 illustrates the antiapoptotic effect of human 
angiopoietin-1 and human VEGF on HUVECs for day 14. 
It was observed that, on day 14, the proteins coencapsulated 
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Figure 7 Fluorescent microscope images showing antiapoptotic effect of human angiopoietin-1 and human VegF on hUVecs at day 14. Bar, 50 µm. It was observed 
that on day 14, the proteins coencapsulated in the nanoparticles significantly decreased HUVEC apoptosis compared with the control, as well as the individual proteins. 
human vascular endothelial cells were seeded onto a 96-well plate at a cell density of 2 × 104 cells per well. The medium was then replaced with 0.1 mL of A) nanoparticle 
supernatant, B) nanoparticle supernatant with excess human VegF antibody, C) nanoparticle supernatant with excess human angiopoietin-1 antibody and incubated for 
96 hours. D) control cultures received the same amount of serum-free media without addition of human VegF and human angiopoietin-1 proteins. The numbers of cells 
floating in each well were collected after phosphate-buffered saline washing and counted. The number of apoptotic cells in the adherent cells was then determined after 
96 hours using the MitoTracker® Red CMXRos kit and DAPI nucleic acid staining and counted using fluorescence microscopy. 
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in the nanoparticles significantly decreased HUVEC apop-
tosis compared with the control, as well as the individual 
proteins. The HUVECs were seeded onto a 96-well plate 
at a cell density of 2 × 104 cells per well. After 24 hours, 
the medium was then replaced with 0.1 mL of nanoparticle 
supernatant, nanoparticle supernatant with excess human 
VEGF antibody, or nanoparticle supernatant with excess 
human angiopoietin-1 antibody, and incubated for 96 hours 
as shown in Figures 7A, 7B, and 7C. Control cultures received 
the same amount of serum-free media without proteins, as 
shown in Figure 7D.
Conclusion
In summary, we examined the in vitro effect of applica-
tion of the angiogenic proteins, human VEGF and human 
angiopoietin-1, coencapsulated in albumin nanoparticles, on 
therapeutic angiogenesis. Our results demonstrate that appli-
cation of a nanoparticle system provided slow, continuous, 
and extended-release kinetics of the proteins which, in turn, 
resulted in an augmented combined effect of the released 
angiogenic proteins on proliferation and antiapoptosis of 
HUVECs in comparison with the released individual proteins. 
Future perspectives could involve in vivo studies demonstrat-
ing the potential of clinical application of this system towards 
therapeutic angiogenesis.
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